Quality/Regulatory

Why the EU Considers Prescription Support Software a Medical Device

SNITEM & Philips France vs. Health Minister: the ECJ defines the conditions under which software for assistance to the medical prescription can be qualified medical device within the meaning of the Directive.

Share this:

The European Court of Justice (ECJ) has just made its decision in the case C329/16 SNITEM & Philips France vs. Health Minister, and endorsed the conclusions of the Advocate General.

The ECJ holds that a prescription support software (LAP) constitutes a medical device within the meaning of Directive 93/42 when one of the functionalities of this software allows the exploitation of data specific to a patient in particular to detect contraindications, drug interactions and excessive doses, even if such software does not act directly in or on the human body. However, the ECJ adds that it is only this functionality that constitutes a medical device (§ 40).

The solution is significant, because if the Directive provides, since 2007, that a software “is a medical device when specifically intended by the manufacturer to be used in one or several (…) medical purposes”, no decision from the ECJ had ever determined, so far, the conditions under which software could be qualified as a medical device.

Beyond the case before the Conseil d’Etat (see below), the decision of the ECJ to intervene is of prime importance for the LAP’s manufacturers and publishers.

Background

Philips France (Philips) manufactures and commercializes the prescription support software called “Intellispace Critical Care and Anesthesia” (ICCA). This software provides physicians with information required for appropriately prescribing medicines, notably concerning contraindications, drugs interactions and excessive doses. ICCA has obtained CE mark, which evidences conformity of such software to the requirements provided by the Directive.

SNITEM and Philips have launched two actions before the Conseil d’Etat asking for the withdrawal of French Decree No. 2014-1359 of 14 November 2014 relating to the obligation to obtain a certification for all prescription support software and dispensation support software. Claimants have put forward that the certification requirement does not comply with European law since the Decree requires that some software, including those which have already obtained CE mark (such as ICCA), provide a certification issued by French authority.

The preliminary question submitted by the Conseil d’Etat

Upon receiving this request, the Conseil d’Etat first questioned of whether software such as ICCA is medical device within the meaning of the Directive. In fact, arguments subjected to it first require the Conseil d’Etat to distinguish between software that is not qualified as medical device and software that is and for which only applicants’ argument is likely to be upheld.

The preliminary question submitted by the Conseil d’Etat to the ECJ is as follows:

“Must [Council] Directive 93/42/EEC of 14 June 1993 [concerning medical devices] be interpreted as meaning that software, the purpose of which is to offer to prescribers practising in towns, a health establishment or a medico-social establishment support for determining a drug prescription, in order to improve the safety of prescription, facilitate the work of the prescriber, encourage conformity of the prescription with national regulatory requirements and reduce the cost of treatment at the same quality, constitutes a medical device within the meaning of that directive, where that software has at least one function that permits the use of data specific to a patient to help his doctor issue his prescription, in particular by detecting contraindications, drug interactions and excessive doses, even though it does not itself act in or on the human body?”

It is from this preliminary question that the ECJ was seized on June 13, 2016.

Reasoning of the ECJ

Based on the interpretation of the Directive and the relevant case law of the ECJ to this issue (in particular Brain Products and Oliver Medical), as well as on the MEDDEVs, the ECJ, unlike the solution defended by the French Government, responds to the Conseil d’Etat that a software is qualified as medical device when it “provides the physician with information that allows him to detect contraindications, drug interactions and excessive doses”.

The qualification criteria provided by the Directive and the MEDDEVs

In reaching this conclusion, and in summary, the ECJ first recalls that it is expressly stated in Article 1 (2) of Directive 93/42 that software constitutes a medical device when it satisfies both conditions of any such software, relating respectively to (i) the purpose pursued and (ii) the effect achieved.

Concerning the criteria relating to the purpose pursued by the software

According to the ECJ, the European legislator expressly provided that software itself is a medical device when it is specifically intended by the manufacturer to be used in one or several of the medical purposes contained in the definition of a medical device, a software with a general use used in a medical environment not being a medical device. Thus, as reminded by the ECJ, in order for software to fall within the scope of Directive 93/42, it is not enough for it to be used in a medical context, but it is necessary that their destination, defined by their manufacturer, being specifically medical (Decision dated 22 November 2012, Brain Products, C-219/11, EU: C: 2012:742, points 16 and 17).

In contrast, the ECJ specifies that software that “cross-checks the data specific to a patient with the drugs that the physician plans to prescribe and is thus able to provide, in an automated way, an analysis to detect, in particular, any contraindications, drug interactions and excessive doses, is used for the purpose of prevention, control, treatment or mitigation of disease and therefore pursues a purpose specifically medical” (§ 25).

However, as the Advocate General has pointed out (which has not been disputed on this point), ICCA provides assistance with medical prescription in anesthesia departments and intensive care units. In the first case, as soon as the patient is admitted, the software integrates both the information prior to an operation and those available in the systems to which the software is connected; it analyzes and processes this data to provide the anesthetist with the information he needs during the operation. For intensive care, reanimation or constant care units, the program is capable of managing the many unique patient characteristics required for medical decision making. In both cases, ICCA includes an engine that allows physicians and health professionals to calculate prescription of drugs, possible allergies or duration of treatment.

As the Attorney General stated in its conclusions, the collection, the analysis and the processing of patient’s data—operations at which ICCA helps healthcare professionals detect contraindications, interactions between drugs and excessive doses – remove this computer tool from those which have only a purely administrative character (argument advanced by the French Government). He added: “From the patient’s collected data (which may come from other systems or devices this patient is connected to) and with the help of its computational engines, the software automatically converts this data in useful information for the health professional while suggesting the appropriate doses of the drug (…)” this functionality allowing “the exploitation of data specific to a patient to help his physician to establish his prescription”.

Therefore, in view of the aforementioned functions of ICCA, the ECJ follows the conclusions of the Advocate General who had noted that ICCA was an instrumental means at the service of health professionals, which it facilitates the therapeutic and control tasks of patients under anesthesia or intensive care.

Concerning the condition relating to the effect achieved

The Conseil d’Etat wondered whether software that does not act by itself in or on the human body can be a medical device within the meaning of Directive 93/42.

Unsurprisingly, the ECJ recalls in its decision that Recital 6 of Directive 2007/47 suggests that the purpose of the use of the software counts, and not the way in which the effect it is able to produce on or in the human body.

For the reasons given above, the ECJ responded to the question raised by the Conseil d’Etat as follows: “The answer to the preliminary question must be that Article 1 (1) and Article 1 (2) (a) of Directive 93/42 must be interpreted in that a software with one of the functionalities enables the use of data specific to a patient, in particular for detecting contraindications, drug interactions and excessive doses, is, for this functionality, a medical device, within the meaning of these provisions, even if such software does not act directly in or on the human body” (§39).

The ECJ finally duly recalls the consequences of this qualification.

The ECJ thus specifies, in direct connection with the context of the preliminary question submitted to it, that when software is qualified as a medical device, it must compulsorily be CE marked when it is placed on the market. Once this marking has been obtained, this product, with regard to this functionality, can be placed on the market and move freely within the Union without having to undergo any other additional procedure, such as a new certification (ECJ, Decision dated 19 November 2009, Nordiska Dental, C 288/08, EU: C: 2009: 718, item 21).

However, only functionalities that meet the definition of a medical device fall within the scope of the Directive and must be CE marked. It is therefore the responsibility of the manufacturer to identify the limits and interfaces of the different modules which, in the case of modules subject to Directive 93/42, must be clearly identified by the manufacturer and based on the use to be made of the product, in accordance with the guidelines in this area (§ 37). As a result, the manufacturer of such prescription assistance software is required to identify which of the modules constitute medical devices, so that the CE marking can be affixed to these modules alone.

The consequence for the validity of the certification scheme imposed by the Public Health Code is not neutral. It will be up to the Conseil d’Etat to decide on the opposability of this procedure for LAPs containing a functionality that qualifies such software as a medical device.

Beyond the specific case and the future of the 2014 Decree, the Court’s interpretation of the Directive has immediate and major consequences for the industrials concerned, since the marketing in each Member State of software that must be qualified as medical device is subject to very strict and binding requirements.

The decision in this case, based on the provisions of Directive 93/42/CE, is of interest with the aim of the application of the new Regulation No. 2017/745, which has retained – by further detailing – the dual category of software for medical purposes on the one hand and software with a general use used in a medical environment. If, unlike the former, the latter are not medical devices, the medical functionalities carried by the software will remain key in the determination of the medical purpose pursued, and therefore of the medical device qualification.

About The Author

Emmanuel Garnier is an expert on regulatory and litigation issues faced by companies acting in Life Sciences, with a particular focus on MedTech companies. Emmanuel frequently advises companies acting in eHealth in relation to qualification and classification issues, as well as data protection and security. He notably provides strategic advice and assistance to clients on market access (pricing and reimbursement) and enforcement actions from regulatory agencies. Emmanuel is also a litigator assisting medical devices companies in product safety and product liability matters with local or cross-border implications. He can be reached at Emmanuel.garnier@simmons-simmons.com.

Upcoming Events & Webinars

The regulations are there for anyone to read, but even the largest, best-prepared companies have large teams struggling with implementation. There is no easy answer, but we are all in this together, and by pooling thoughts and solutions can expedite the process for everyone. This two-day workshop convenes experts from major companies, notified bodies, and consulting firms to share strategies, procedures, experiences, and challenges.

CAPA is the most critical and challenging quality system requirement in terms of complex thinking and organizational processes. Not a CAPA 101 course, this workshop brings together leading industry CAPA process owners to discuss approaches to the most difficult problems in CAPA and root cause analysis. Registration will open soon.

Deficiencies in process validation and other aspects of production and process control earn more FDA enforcement actions than any other quality function except CAPA. This two-day workshop addresses key issues in process validation, including risk-based determination of processes to be validated, FDA and 13485:2016 requirements, key process validation elements and best practices, statistical and other tools, maintaining the validated state, and documentation.

The new European medical device regulation imposes a broad array of stringent new requirements on medical device manufacturers. This program takes a high-level approach to the business strategy and organizational challenges of evaluating a company’s portfolio of legacy and pipeline products to determine the impact of the new regulation, perform a gap analysis, calculate the profit and cost of remediation, establish a timed and stratified approach, and to modify or create those internal structures needed to bring current products into compliance and to efficiently maintain compliance in the future. Registration will open soon.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

You can adjust all of your cookie settings by navigating the tabs on the left hand side.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

We use tracking pixels that set your arrival time at our website, this is used as part of our anti-spam and security measures. Disabling this tracking pixel would disable some of our security measures, and is therefore considered necessary for the safe operation of the website. This tracking pixel is cleared from your system when you delete files in your history.

We also use cookies to store your preferences regarding the setting of 3rd Party Cookies.

disable

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

Cookie Policy

A browser cookie is a small piece of data that is stored on your device to help websites and mobile apps remember things about you. Other technologies, including Web storage and identifiers associated with your device, may be used for similar purposes. In this policy, we say “cookies” to discuss all of these technologies.

Our Privacy Policy explains how we collect and use information from and about you when you use This website and certain other Innovative Publishing Co LLC services. This policy explains more about how we use cookies and your related choices.

How We Use Cookies

Data generated from cookies and other behavioral tracking technology is not made available to any outside parties, and is only used in the aggregate to make editorial decisions for the websites. Most browsers are initially set up to accept cookies, but you can reset your browser to refuse all cookies or to indicate when a cookie is being sent by visiting this Cookies Policy page. If your cookies are disabled in the browser, neither the tracking cookie nor the preference cookie is set, and you are in effect opted-out.

In other cases, our advertisers request to use third-party tracking to verify our ad delivery, or to remarket their products and/or services to you on other websites. You may opt-out of these tracking pixels by adjusting the Do Not Track settings in your browser, or by visiting the Network Advertising Initiative Opt Out page.

You have control over whether, how, and when cookies and other tracking technologies are installed on your devices. Although each browser is different, most browsers enable their users to access and edit their cookie preferences in their browser settings. The rejection or disabling of some cookies may impact certain features of the site or to cause some of the website’s services not to function properly.

Individuals may opt-out of 3rd Party Cookies used on IPC websites by adjusting your cookie preferences through this Cookie Preferences tool, or by setting web browser settings to refuse cookies and similar tracking mechanisms. Please note that web browsers operate using different identifiers. As such, you must adjust your settings in each web browser and for each computer or device on which you would like to opt-out on. Further, if you simply delete your cookies, you will need to remove cookies from your device after every visit to the websites. You may download a browser plugin that will help you maintain your opt-out choices by visiting www.aboutads.info/pmc. You may block cookies entirely by disabling cookie use in your browser or by setting your browser to ask for your permission before setting a cookie. Blocking cookies entirely may cause some websites to work incorrectly or less effectively.

The use of online tracking mechanisms by third parties is subject to those third parties’ own privacy policies, and not this Policy. If you prefer to prevent third parties from setting and accessing cookies on your computer, you may set your browser to block all cookies. Additionally, you may remove yourself from the targeted advertising of companies within the Network Advertising Initiative by opting out here, or of companies participating in the Digital Advertising Alliance program by opting out here.